Economic evaluation of sunitinib vs. interferon-alfa (IFN-alfa) in first-line treatment of Metastatic Renal Cell Carcinoma (MRCC) in Colombia

被引：0

作者：

Godoy, J., I ^{[1
]}

Cardona, A. F. ^{[2
]}

Alvis, N. ^{[3
]}

Arango, C. H. ^{[4
]}

Romero, M. ^{[4
]}

Spath, A. ^{[5
]}

Ramirez, P. ^{[5
]}

Caceres, H. A. ^{[5
]}

Quijano, M. F. ^{[6
]}

机构：

[1] Cent Mil Hosp, Bogota DC, Colombia

[2] Hosp Univ San Ignacio, Bogota DC, Colombia

[3] Univ Cartagena, Cartagena, Colombia

[4] Synergia Consultoria & Gest SA, Bogota DC, Colombia

[5] Pfizer SA, Bogota DC, Colombia

[6] Univ Sabana, Bogota DC, Colombia

来源：

VALUE IN HEALTH | 2008年 / 11卷 / 03期

关键词：

D O I：

10.1016/S1098-3015(10)70324-7

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A100 / A100

页数：1

共 50 条

[1] Economic evaluation of sunitinib vs. interferon-alfa (IFN-α) in first-line metastatic renal cell carcinoma (mRCC)
Negrier, S.
Remak, E.
Brown, R.
Kim, S. T.
Charbonneau, C.
Motzer, R. J.
[J]. EJC SUPPLEMENTS, 2007, 5 (04): : 303 - 303
[2] Economic evaluations of sunitinib versus interferon-alfa (IFN-α) in first-line metastatic renal cell carcinoma (mRCC)
Remak, E.
Mullins, C. D.
Akobundu, E.
Charbonneau, C.
Woodruff, K.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[3] OVERALL SURVIVAL WITH SUNITINIB VERSUS INTERFERON-ALFA (IFN-□) AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC)
Szczylik, C.
Negrier, S.
Oudard, S.
Figlin, R. A.
Hutson, T. E.
Tomczak, P.
Michaelson, M. D.
Bukowski, R. M.
Huang, X.
Kim, S. T.
Chen, I
Motzer, R. J.
[J]. EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 182 - 182
[4] OVERALL SURVIVAL WITH SUNITINIB VERSUS INTERFERON (IFN)-ALFA AS FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC)
Negrier, S.
Figlin, R. A.
Hutson, T. E.
Tomczak, P.
Michaelson, M. D.
Bukowski, R. M.
Huang, X.
Kim, S. T.
Chen, I.
Motzer, R. J.
[J]. ANNALS OF ONCOLOGY, 2008, 19 : 190 - 190
[5] Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC)
Figlin, R. A.
Hutson, T. E.
Tomczak, P.
Michaelson, M. D.
Bukowski, R. M.
Negrier, S.
Huang, X.
Kim, S. T.
Chen, I.
Motzer, R. J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[6] Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors
Motzer, R. J.
Figlin, R. A.
Hutson, T. E.
Tomczak, P.
Bukowski, R. M.
Rixe, O.
Bjarnason, G. A.
Kim, S. T.
Chen, I.
Michaelson, D.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[7] Sunitinib plus interferon-alfa in the first-line treatment for metastatic renal cell carcinoma (mRCC): results of a dose-finding study
Kondagunta, G. V.
Hudes, G.
Figlin, R.
Wilding, G.
Hariharan, S.
Kempin, S.
Fayyad, R.
Hoosen, S.
Motzer, R. J.
[J]. EJC SUPPLEMENTS, 2007, 5 (04): : 305 - 305
[8] Characterizing prior nephrectomy patients with metastatic renal cell carcinoma (mRCC) treated with first-line sunitinib versus interferon-alfa
Figlin, R. A.
Hutson, T. E.
Tomczak, P.
Michaelson, M. D.
Bjarnason, G. A.
Lin, X.
Lowenthal, S. Pitman
Korytowsky, B.
Matczak, E.
Oudard, S.
[J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S644 - S645
[9] Sunitinib vs. interferon-alpha (IFN-alpha) in first-line metastatic renal cell carcinoma (mRCC): An economic evaluation
Remak, E.
Brown, R.
Negrier, S.
Motzer, R. J.
Kim, S. T.
Charbonneau, C.
[J]. VALUE IN HEALTH, 2007, 10 (06) : A327 - A328
[10] Quality of life (QOL) with sunitinib versus interferon-alfa (IFN-α) as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): Final results
Cella, D.
Michaelson, M. D.
Cappelleri, J. C.
Bushmakin, A. G.
Charbonneau, C.
Kim, S. T.
Li, J. Z.
Motzer, R. J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)

← 1 2 3 4 5 →